Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

77.38USD
5:37pm BST
Change (% chg)

$0.31 (+0.40%)
Prev Close
$77.07
Open
$77.19
Day's High
$77.64
Day's Low
$76.90
Volume
259,805
Avg. Vol
997,540
52-wk High
$86.71
52-wk Low
$64.25

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $84,853.22
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.70

Financials

  LLY.N Industry Sector
P/E (TTM): 33.40 30.61 31.81
EPS (TTM): 2.31 -- --
ROI: 8.49 14.48 14.02
ROE: 17.03 15.57 15.34

CVS Health's dull third-quarter forecast overshadows profit beat

CVS Health Corp forecast current quarter profit below Wall Street estimates and said it has been ordered to cooperate with investigations into possible false claims submitted to a government healthcare program and drug pricing.

08 Aug 2017

UPDATE 3-CVS Health's dull Q3 forecast overshadows profit beat

* Shares down 1.4 pct (Adds investor comment, company response; updates shares)

08 Aug 2017

BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine

* Eli Lilly announces positive results for second phase 3 study of Lasmiditan for the acute treatment of Migraine

04 Aug 2017

Fitch Downgrades AstraZeneca to 'A-'; Outlook Negative

(The following statement was released by the rating agency) LONDON, August 01 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating to 'A-' from 'A'. The Outlook is Negative. The downgrade reflects AstraZeneca's increasing business risk as the pharmaceutical group transitions into next-generation therapies. The company's recent mixed late-stage pipeline developments in oncology - an increasing

01 Aug 2017

BRIEF-Lilly gets civil investigative demand from Minnesota AG for insulin product pricing‍​

* Says got civil investigative demand from Minnesota's office of Attorney General relating to pricing, sale of insulin products - SEC filing‍​

28 Jul 2017

US STOCKS-S&P hits record on strong earnings; Alphabet drags Nasdaq

* Indexes up: Dow 0.59 pct, S&P 0.39 pct, Nasdaq 0.07 pct (Updates to early afternoon)

25 Jul 2017

Lilly signals long delay for arthritis drug, shares fall

Eli Lilly and Co on Tuesday outlined a likely multi-year delay for its experimental rheumatoid arthritis drug with blockbuster sales potential, and disappointed investors sent its shares down nearly 4 percent.

25 Jul 2017

US STOCKS-Strong earnings boost S&P, Dow; Alphabet drags Nasdaq

* Dow up 0.49 pct, S&P up 0.34 pct, Nasdaq down 0.06 pct (Adds details, changes comment, updates prices)

25 Jul 2017

BRIEF-Eli lilly says seeks external early cancer assets

* Eli Lilly says intends to be more active seeking external preclinical and early stage immuno-oncology assets

25 Jul 2017

Drugmaker Lilly's profit jumps 35 percent

July 25 Eli Lilly and Co on Tuesday reported a 35 percent rise in quarterly profit as the U.S. drugmaker benefited from higher sales of its diabetes treatment Trulicity as well as its psoriasis drug Taltz.

25 Jul 2017

Competitors

Earnings vs. Estimates